So if you look at our operating spend, the S&M is down about a million bucks versus the last quarter. And historically, our second quarter is generally pretty high for the sales and marketing because of all the conferences that we have in the current quarter. So that's the first part. So we are definitely on the right trajectory in the sales and marketing. The second piece on the R&D, again, I think the team has done a great job in terms of making sure that we are working on the prioritized projects and they're able to kind of manage the expenses, and I think the number is down about $3.5 to $4 million there as well. So I think we have made good progress in those two lines. On the GNA, of course, because of the legal spend, we were not able to see the impact that we wanted to basically see on that particular line. The last but not the least is the cost of testing services. You might see that cost of testing services is pretty similar to what we had in the last quarter. But last quarter, I just want to highlight that we had the one time Stanford accrual royalty reversal. And that basically had brought a cost of testing services down last quarter. So if you were to compare the cost of testing services for say, Q4 of last year or Q3, you probably will see that we have saved about $3 to $4 million, both as a function of volume and some of the things that we are trying to do as a company. So in summary, I'm basically, what I'm suggesting here is that we are making good progress on

Aug 8, 2023 / receipt, needs a key / Abhishek, other | earnings call 2023-08-08 | transcript 6d40f57a-2f7b-4a1a-86b4-59de6ee5ec15 | chars 45522-47022 | segment 47

Yeah, the shortages you've seen across the healthcare network is pretty well documented. I think, you know, during the process of COVID, there was a lot of staff who were firstly leaving roles and going to other institutions. It became this whole traveling nurse concept. And so there was staffing shortages as a result of that. Secondly, there were people who were leaving nursing roles and other roles as part of that during the course of COVID. And so it left those roles firmly. Those two have been pretty significant, pivotal creations of staffing shortages across the hospital landscape and is left to various institutions actually being short in this Where this has really played a role, though, is when we saw during Q3 in 2020 during COVID that there were a lot of elective procedures being done on weekends, for example, play catch-up as part of living donor transplants. And so even if there is a desire to do more, for example, in transplants, you're not seeing that same sort of willingness or availability, for example, to schedule ORs out of hours or to schedule on weekends, for example. So it has been something that still exists. And living donors have not returned back to pre-COVID levels.

Aug 4, 2022 / receipt, needs a key / Raj, other | earnings call 2022-08-04 | transcript f2e813f3-6b0d-42b8-bca3-8c6c3dd1af91 | chars 37452-38661 | segment 37

Yeah, I think for staffing shortages, it's harder for us to say that, you know, centres will, you know, be able to recover. But I think, you know, general as a whole in what we're seeing across the landscape is there has been, you know, an acceptance of, COVID, there's also been acceptance of, you know, people now trying to get back more of a sense of normalcy. So on the first factor, the traveling nurses, you'll see a bit of a trend shift there as well, where the actual payment rates and, you know, the desire to keep on moving around will probably change with payments coming down to that. So there'll be quite a difference. The second is you'll probably see less of the attrition of people wanting to retire because that has already happened. So I think it's now really dependent on more folks coming back into the into those situations, but also there being lower attrition. It's harder for us to make a macro comment of the entire United States.

Aug 4, 2022 / receipt, needs a key / Raj, other | earnings call 2022-08-04 | transcript f2e813f3-6b0d-42b8-bca3-8c6c3dd1af91 | chars 38771-39726 | segment 39

Non-gap operating expenses for the second quarter were $62.4 million, up about $2 million sequentially from Q122. The increase in our operating expenses was driven by sales and marketing expenses in a conference-heavy quarter. We remain disciplined with our spend and plan to keep operating expenses flattish in the second half.

Aug 4, 2022 / receipt, needs a key / Abhishek, Interim CFO | earnings call 2022-08-04 | transcript f2e813f3-6b0d-42b8-bca3-8c6c3dd1af91 | chars 17401-17729 | segment 17

We maintained our adjusted EBITDA margin versus Q1 despite increased costs in a conference-heavy spend quarter.

Aug 4, 2022 / receipt, needs a key / Reg, CEO | earnings call 2022-08-04 | transcript f2e813f3-6b0d-42b8-bca3-8c6c3dd1af91 | chars 4804-4915 | segment 4

2022 Guidance of $330 to $350 Million*

ir_statement / Sep 16, 2026 / receipt

Grow ex-US Products Business

ir_statement / Sep 16, 2026 / receipt

Low double-digit decline in overall ASP

ir_statement / Sep 16, 2026 / receipt

Low double-digit decline in overall ASP

ir_statement / Sep 16, 2026 / receipt

Adjusted EBITDA Losses ($20M) - ($30M)

ir_statement / Sep 16, 2026 / receipt

Expected to be at the high end of the range

ir_statement / Sep 16, 2026 / receipt

Total Revenue $260M - $274M

ir_statement / Sep 16, 2026 / receipt

Expanded payer coverage by 14 million lives

ir_statement / Sep 16, 2026 / receipt

Raised 2024 revenue guidance to $274 - $282 million

ir_statement / Sep 16, 2026 / receipt

Revenue Guidance of $324M at the Mid-Point

ir_statement / Sep 16, 2026 / receipt

Raised 2024 guidance for annual revenue to $320 to $328 million and adjusted EBITDA to a gain of $9 to $15 million.

ir_statement / Sep 16, 2026 / receipt

Lower operating expenses

ir_statement / Sep 16, 2026 / receipt